Insight 数据库显示,2025 年以来,中国生物制药已经有18 款 1 类新药首次在国内获批临床。从药物类型来看,包括 3 款 ADC(包括 1 款双抗 ADC)、3 款单抗、4 款双抗、8 款化药。本文将介绍其中的 10 款生物药,仅供读者参考。TQB2922(皮下注射):EGFR/c-Met 双抗11 月 18 日,正大天晴申报的 TQB2922 注射液(皮下注射)获得临床试验默示许可,...
Source LinkInsight 数据库显示,2025 年以来,中国生物制药已经有18 款 1 类新药首次在国内获批临床。从药物类型来看,包括 3 款 ADC(包括 1 款双抗 ADC)、3 款单抗、4 款双抗、8 款化药。本文将介绍其中的 10 款生物药,仅供读者参考。TQB2922(皮下注射):EGFR/c-Met 双抗11 月 18 日,正大天晴申报的 TQB2922 注射液(皮下注射)获得临床试验默示许可,...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.